Targeting leukotriene B₄ in inflammation

Bibliography

• Haeggström JZ, Funk CD. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 2011;111(10):5866-98
   PubMed Web of Science ®Google Scholar
• Nakamura M, Shimizu T. Leukotriene receptors. Chem Rev 2011;111(10):6231-98
   Google Scholar
• Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980;288(5790):484-6
   PubMed Web of Science ®Google Scholar
• Ford-Hutchinson AW, Bray MA, Doig MV, et al. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980;286(5770):264-5
   PubMed Web of Science ®Google Scholar
• Palmblad J, Malmsten CL, Uden AM, et al. Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood 1981;58(3):658-61
   Google Scholar
• Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237(4819):1171-6
   PubMed Web of Science ®Google Scholar
• Ryan A, Godson C. Lipoxins: regulators of resolution. Curr Opin Pharmacol 2010;10(2):166-72
   PubMed Web of Science ®Google Scholar
• Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 2011;111(10):5922-43
   PubMed Web of Science ®Google Scholar
• Borgeat P, Samuelsson B. Metabolism of arachidonic acid in polymorphonuclear leukocytes. Structural analysis of novel hydroxylated compounds. J Biol Chem 1979;254(16):7865-9
   Google Scholar
• Borgeat P, Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc Natl Acad Sci USA 1979;76(7):3213-17
   Google Scholar
• Lee SP, Serezani CH, Medeiros AI, et al. Crosstalk between prostaglandin E2 and leukotriene B4 regulates phagocytosis in alveolar macrophages via combinatorial effects on cyclic AMP. J Immunol 2009;182(1):530-7
   Google Scholar
• Okamoto F, Saeki K, Sumimoto H, et al. Leukotriene B4 augments and restores FcγRs-dependent phagocytosis in macrophages. J Biol Chem 2010;285(52):41113-21
   PubMed Web of Science ®Google Scholar
• Serezani CH, Kane S, Collins L, et al. Macrophage dectin-1 expression is controlled by leukotriene B4 via a GM-CSF/PU.1 axis. J Immunol 2012;189(2):906-15
   Google Scholar
• Flamand L, Tremblay MJ, Borgeat P. Leukotriene B4 triggers the in vitro and in vivo release of potent antimicrobial agents. J Immunol 2007;178(12):8036-45
   PubMed Web of Science ®Google Scholar
• Gaudreault E, Gosselin J. Leukotriene B4 induces release of antimicrobial peptides in lungs of virally infected mice. J Immunol 2008;180(9):6211-21
   PubMedGoogle Scholar
• Wan M, Sabirsh A, Wetterholm A, et al. Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses. Faseb J 2007;21(11):2897-905
   PubMed Web of Science ®Google Scholar
• Widegren H, Andersson M, Borgeat P, et al. LTB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects. Respir Med 2011;105(7):997-1006
   Google Scholar
• Costa MF, de Souza-Martins R, de Souza MC, et al. Leukotriene B4 mediates γδ T lymphocyte migration in response to diverse stimuli. J Leukoc Biol 2009;87(2):323-32
   Google Scholar
• Goodarzi K, Goodarzi M, Tager AM, et al. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 2003;4(10):965-73
   PubMed Web of Science ®Google Scholar
• Islam SA, Thomas SY, Hess C, et al. The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood 2006;107(2):444-53
   Google Scholar
• Kihara Y, Yokomizo T, Kunita A, et al. The leukotriene B4 receptor, BLT1, is required for the induction of experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 2010;394(3):673-8
   Google Scholar
• Klein E, Liu A, Claesson HE. Activation of innate immunity by the leukotriene B4 inhibits EBV induced B-cell transformation in cord-blood derived mononuclear cultures. Immunol Lett 2008;116(2):174-7
   Google Scholar
• Liu A, Claesson HE, Mahshid Y, et al. Leukotriene B4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures. Blood 2008;111(5):2693-703
   Google Scholar
• Tager AM, Bromley SK, Medoff BD, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003;4(10):982-90
   PubMedGoogle Scholar
• Devchand PR, Keller H, Peters JM, et al. The PPARα-leukotriene B4 pathway to inflammation control. Nature 1996;384(6604):39-43
   PubMed Web of Science ®Google Scholar
• Orasanu G, Ziouzenkova O, Devchand PR, et al. The peroxisome proliferator-activated receptor-γ agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-α-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol 2008;52(10):869-81
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007;357(18):1841-54
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh N, Shingu M, Nobunaga M, Tawara T. Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fluids. Inflammation 1991;15(6):497-503
   PubMed Web of Science ®Google Scholar
• Gheorghe KR, Korotkova M, Catrina AI, et al. Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. Arthritis Res Ther 2009;11(3):R83
   Google Scholar
• Klickstein LB, Shapleigh C, Goetzl EJ. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J Clin Invest 1980;66(5):1166-70
   PubMedGoogle Scholar
• Rae SA, Davidson EM, Smith MJ. Leukotriene B4, an inflammatory mediator in gout. Lancet 1982;2(8308):1122-4
   PubMedGoogle Scholar
• Chou RC, Kim ND, Sadik CD, et al. Lipid-cytokine-chemokine cascade drives neutrophil recruitment in a murine model of inflammatory arthritis. Immunity 2010;33(2):266-78
   PubMed Web of Science ®Google Scholar
• Kim ND, Chou RC, Seung E, et al. A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med 2006;203(4):829-35
   PubMed Web of Science ®Google Scholar
• Sadik CD, Kim ND, Iwakura Y, Luster AD. Neutrophils orchestrate their own recruitment in murine arthritis through C5αR and FcγR signaling. Proc Natl Acad Sci USA 2012;109(46):E3177-85
   Google Scholar
• Anderson GD, Keys KL, De Ciechi PA, Masferrer JL. Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. Inflamm Res 2009;58(2):109-17
   Google Scholar
• Chen M, Lam BK, Luster AD, et al. Joint tissues amplify inflammation and alter their invasive behavior via leukotriene B4 in experimental inflammatory arthritis. J Immunol 2010;185(9):5503-11
   PubMed Web of Science ®Google Scholar
• Shao WH, Del Prete A, Bock CB, Haribabu B. Targeted disruption of leukotriene B4 receptors BLT1 and BLT2: a critical role for BLT1 in collagen-induced arthritis in mice. J Immunol 2006;176(10):6254-61
   PubMed Web of Science ®Google Scholar
• Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10(3):181-93
   PubMed Web of Science ®Google Scholar
• Tong WG, Ding XZ, Hennig R, et al. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin Cancer Res 2002;8(10):3232-42
   PubMed Web of Science ®Google Scholar
• Hoque A, Lippman SM, Wu TT, et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 2005;26(4):785-91
   Google Scholar
• Matsuyama M, Yoshimura R, Mitsuhashi M, et al. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol 2004;24(4):821-7
   Google Scholar
• De Caterina R, Mazzone A, Giannessi D, et al. Leukotriene B4 production in human atherosclerotic plaques. Biomed Biochim Acta 1988;47(10-11):S182-5
   PubMedGoogle Scholar
• Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 1998;97(24):2406-13
   PubMed Web of Science ®Google Scholar
• Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003;100(3):1238-43
   PubMed Web of Science ®Google Scholar
• Qiu H, Gabrielsen A, Agardh HE, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 2006;103(21):8161-6
   PubMed Web of Science ®Google Scholar
• Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 2005;4(8):664-72
   PubMed Web of Science ®Google Scholar
• Cao RY, St Amand T, Grabner R, et al. Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis 2009;203(2):395-400
   PubMed Web of Science ®Google Scholar
• Yu Z, Crichton I, Tang SY, et al. Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc Natl Acad Sci USA 2012;109(17):6727-32
   Google Scholar
• Zhao L, Moos MP, Grabner R, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004;10(9):966-73
   Google Scholar
• Houard X, Ollivier V, Louedec L, et al. Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus. Faseb J 2009;23(5):1376-83
   Google Scholar
• Ahluwalia N, Lin AY, Tager AM, et al. Inhibited aortic aneurysm formation in BLT1-deficient mice. J Immunol 2007;179(1):691-7
   Google Scholar
• Kristo F, Hardy GJ, Anderson TJ, et al. Pharmacological inhibition of BLT1 diminishes early abdominal aneurysm formation. Atherosclerosis 2010;210(1):107-13
   Google Scholar
• Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006;58(3):375-88
   PubMed Web of Science ®Google Scholar
• Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 2009;50(Suppl):S237-42
   PubMed Web of Science ®Google Scholar
• Clark JD, Schievella AR, Nalefski EA, Lin LL. Cytosolic phospholipase A2. J Lipid Mediat Cell Signal 1995;12(2-3):83-117
   Google Scholar
• Gilbert NC, Bartlett SG, Waight MT, et al. The structure of human 5-lipoxygenase. Science 2011;331(6014):217-19
   PubMed Web of Science ®Google Scholar
• Luo M, Jones SM, Phare SM, et al. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem 2004;279(40):41512-20
   PubMed Web of Science ®Google Scholar
• Werz O, Klemm J, Samuelsson B, Radmark O. 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc Natl Acad Sci USA 2000;97(10):5261-6
   Google Scholar
• Werz O, Szellas D, Steinhilber D, Radmark O. Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). J Biol Chem 2002;277(17):14793-800
   Google Scholar
• Luo M, Jones SM, Flamand N, et al. Phosphorylation by protein kinase a inhibits nuclear import of 5-lipoxygenase. J Biol Chem 2005;280(49):40609-16
   Google Scholar
• Pergola C, Rogge A, Dodt G, et al. Testosterone suppresses phospholipase D, causing sex differences in leukotriene biosynthesis in human monocytes. Faseb J 2011;25(10):3377-87
   Google Scholar
• Evans JF, Ferguson AD, Mosley RT, Hutchinson JH. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 2008;29(2):72-8
   Google Scholar
• Rakonjac M, Fischer L, Provost P, et al. Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production. Proc Natl Acad Sci USA 2006;103(35):13150-5
   Google Scholar
• Rudberg PC, Tholander F, Thunnissen MM, Haeggström JZ. Leukotriene A4 hydrolase/aminopeptidase. Glutamate 271 is a catalytic residue with specific roles in two distinct enzyme mechanisms. J Biol Chem 2002;277(2):1398-404
   Google Scholar
• Mueller MJ, Blomster M, Oppermann UC, et al. Leukotriene A4 hydrolase: protection from mechanism-based inactivation by mutation of tyrosine-378. Proc Natl Acad Sci USA 1996;93(12):5931-5
   Google Scholar
• Griffin KJ, Gierse J, Krivi G, Fitzpatrick FA. Opioid peptides are substrates for the bifunctional enzyme LTA4 hydrolase/aminopeptidase. Prostaglandins 1992;44(3):251-7
   PubMedGoogle Scholar
• Snelgrove RJ, Jackson PL, Hardison MT, et al. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010;330(6000):90-4
   PubMed Web of Science ®Google Scholar
• Yokomizo T, Izumi T, Chang K, et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997;387(6633):620-4
   PubMed Web of Science ®Google Scholar
• Ott VL, Cambier JC, Kappler J, et al. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol 2003;4(10):974-81
   Google Scholar
• Heller EA, Liu E, Tager AM, et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 2005;112(4):578-86
   PubMed Web of Science ®Google Scholar
• Qiu H, Johansson AS, Sjostrom M, et al. Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4. Proc Natl Acad Sci USA 2006;103(18):6913-18
   Google Scholar
• Nieves D, Moreno JJ. Role of 5-lipoxygenase pathway in the regulation of RAW 264.7 macrophage proliferation. Biochem Pharmacol 2006;72(8):1022-30
   Google Scholar
• Watanabe S, Yamasaki A, Hashimoto K, et al. Expression of functional leukotriene B4 receptors on human airway smooth muscle cells. J Allergy Clin Immunol 2009;124(1):59-65; e1-3
   Google Scholar
• Yokomizo T, Kato K, Terawaki K, et al. A second leukotriene B4 receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000;192(3):421-32
   PubMed Web of Science ®Google Scholar
• Yokomizo T, Kato K, Hagiya H, et al. Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem 2001;276(15):12454-9
   Google Scholar
• Okuno T, Iizuka Y, Okazaki H, et al. 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med 2008;205(4):759-66
   PubMedGoogle Scholar
• Iizuka Y, Okuno T, Saeki K, et al. Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis. Faseb J 2010;24(12):4678-90
   PubMedGoogle Scholar
• Matsunaga Y, Fukuyama S, Okuno T, et al. Leukotriene B4 receptor BLT2 negatively regulates allergic airway eosinophilia. Faseb J 2013;27(8):3306-14
   PubMedGoogle Scholar
• Hegen M, Sun L, Uozumi N, et al. Cytosolic phospholipase A2α-deficient mice are resistant to collagen-induced arthritis. J Exp Med 2003;197(10):1297-302
   Google Scholar
• Marusic S, Leach MW, Pelker JW, et al. Cytosolic phospholipase A2α-deficient mice are resistant to experimental autoimmune encephalomyelitis. J Exp Med 2005;202(6):841-51
   Google Scholar
• Uozumi N, Kume K, Nagase T, et al. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 1997;390(6660):618-22
   PubMed Web of Science ®Google Scholar
• Tai N, Kuwabara K, Kobayashi M, et al. Cytosolic phospholipase A2α inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model. Inflamm Res 2010;59(1):53-62
   Google Scholar
• Nagase T, Uozumi N, Aoki-Nagase T, et al. A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates. LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 2003;284(5):L720-6
   PubMed Web of Science ®Google Scholar
• Bellido-Reyes YA, Akamatsu H, Kojima K, et al. Cytosolic phospholipase A2 inhibition attenuates ischemia-reperfusion injury in an isolated rat lung model. Transplantation 2006;81(12):1700-7
   Google Scholar
• Chen XS, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994;372(6502):179-82
   Google Scholar
• Mancuso P, Nana-Sinkam P, Peters-Golden M. Leukotriene B4 augments neutrophil phagocytosis of Klebsiella pneumoniae. Infect Immun 2001;69(4):2011-16
   Google Scholar
• Irvin CG, Tu YP, Sheller JR, Funk CD. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am J Physiol 1997;272(6 Pt 1):L1053-8
   Web of Science ®Google Scholar
• Peters-Golden M, Bailie M, Marshall T, et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002;165(2):229-35
   PubMed Web of Science ®Google Scholar
• Adamek A, Jung S, Dienesch C, et al. Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice. Eur J Pharmacol 2007;571(1):51-4
   Google Scholar
• Yu Z, Ricciotti E, Miwa T, et al. Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury. Circ Res 2013;112(3):432-40
   Google Scholar
• Pergola C, Werz O. 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opin Ther Patent 2010;20(3):355-75
   PubMed Web of Science ®Google Scholar
• Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340(3):197-206
   PubMed Web of Science ®Google Scholar
• Hofmann B, Steinhilber D. 5-Lipoxygenase inhibitors: a review of recent patents (2010 - 2012). Expert Opin Ther Patent 2013;23(7):895-909
   PubMed Web of Science ®Google Scholar
• Tardif JC, L'Allier P L, Ibrahim R, et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 2010;3(3):298-307
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Liu N, Knorr BA, et al. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease. Respir Med 2011;105(3):392-401
   Google Scholar
• Byrum RS, Goulet JL, Griffiths RJ, Koller BH. Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J Exp Med 1997;185(6):1065-75
   Google Scholar
• Brideau C, Chan C, Charleson S, et al. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 1992;70(6):799-807
   Google Scholar
• Depre M, Friedman B, Tanaka W, et al. Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans. Clin Pharmacol Ther 1993;53(5):602-7
   Google Scholar
• Bain G, King CD, Schaab K, et al. Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor. Br J Clin Pharmacol 2013;75(3):779-90
   PubMed Web of Science ®Google Scholar
• Kent SE, Boyce M, Diamant Z, et al. The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma. Clin Exp Allergy 2013;43(2):177-86
   PubMed Web of Science ®Google Scholar
• Byrum RS, Goulet JL, Snouwaert JN, et al. Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice. J Immunol 1999;163(12):6810-19
   Google Scholar
• Orning L, Krivi G, Bild G, et al. Inhibition of leukotriene A4 hydrolase/aminopeptidase by captopril. J Biol Chem 1991;266(25):16507-11
   PubMed Web of Science ®Google Scholar
• Orning L, Krivi G, Fitzpatrick FA. Leukotriene A4 hydrolase. Inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes. J Biol Chem 1991;266(3):1375-8
   PubMed Web of Science ®Google Scholar
• Labaudiniere R, Hilboll G, Leon-Lomeli A, et al. Omega-[(omega-arylalkyl)aryl]alkanoic acids: a new class of specific LTA4 hydrolase inhibitors. J Med Chem 1992;35(17):3156-69
   Google Scholar
• Hogg JH, Ollmann IR, Haeggström JZ, et al. Amino hydroxamic acids as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem 1995;3(10):1405-15
   Google Scholar
• Yuan W, Munoz B, Wong CH, et al. Development of selective tight-binding inhibitors of leukotriene A4 hydrolase. J Med Chem 1993;36(2):211-20
   Google Scholar
• Penning TD. Inhibitors of leukotriene A4 (LTA4) hydrolase as potential anti-inflammatory agents. Curr Pharm Des 2001;7(3):163-79
   PubMed Web of Science ®Google Scholar
• Tsuji F, Miyake Y, Enomoto H, et al. Effects of SA6541, a leukotriene A4 hydrolase inhibitor, and indomethacin on carrageenan-induced murine dermatitis. Eur J Pharmacol 1998;346(1):81-5
   PubMed Web of Science ®Google Scholar
• Tsuji F, Miyake Y, Horiuchi M, Mita S. Involvement of leukotriene B4 in murine dermatitis models. Biochem Pharmacol 1998;55(3):297-304
   PubMed Web of Science ®Google Scholar
• Thunnissen MM, Nordlund P, Haeggström JZ. Crystal structure of human leukotriene A4 hydrolase, a bifunctional enzyme in inflammation. Nat Struct Biol 2001;8(2):131-5
   PubMedGoogle Scholar
• Sandanayaka V, Mamat B, Mishra RK, et al. Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. J Med Chem 2010;53(2):573-85
   PubMed Web of Science ®Google Scholar
• Kirkland TA, Adler M, Bauman JG, et al. Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem 2008;16(9):4963-83
   PubMed Web of Science ®Google Scholar
• Rao NL, Dunford PJ, Xue X, et al. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J Pharmacol Exp Ther 2007;321(3):1154-60
   PubMed Web of Science ®Google Scholar
• Rao NL, Riley JP, Banie H, et al. Leukotriene A4 hydrolase inhibition attenuates allergic airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med 2010;181(9):899-907
   Google Scholar
• Tian W, Jiang X, Tamosiuniene R, et al. Blocking macrophage leukotriene B4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med 2013;5(200):200ra117
   PubMed Web of Science ®Google Scholar
• Whittle BJ, Varga C, Berko A, et al. Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. Br J Pharmacol 2008;153(5):983-91
   Google Scholar
• Hicks A, Monkarsh SP, Hoffman AF, Goodnow R. Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs 2007;16(12):1909-20
   PubMed Web of Science ®Google Scholar
• Kuwabara K, Yasui K, Jyoyama H, et al. Effects of the second-generation leukotriene B4 receptor antagonist, LY293111Na, on leukocyte infiltration and collagen-induced arthritis in mice. Eur J Pharmacol 2000;402(3):275-85
   Google Scholar
• Raychaudhuri A, Kotyuk B, Pellas TC, et al. Effect of CGS 25019C and other LTB4 antagonists in the mouse ear edema and rat neutropenia models. Inflamm Res 1995;44(Suppl 2):S141-2
   Google Scholar
• Hoyer FF, Albrecht L, Nickenig G, Muller C. Selective inhibition of leukotriene receptor BLT-2 reduces vascular oxidative stress and improves endothelial function in ApoE-/- mice. Mol Cell Biochem 2012;359(1-2):25-31
   Google Scholar
• Schmitt-Grohe S, Zielen S. Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects. Paediatr Drugs 2005;7(6):353-63
   Google Scholar
• Flamand L, Borgeat P, Lalonde R, Gosselin J. Release of anti-HIV mediators after administration of leukotriene B4 to humans. J Infect Dis 2004;189(11):2001-9
   PubMed Web of Science ®Google Scholar
• Hofheinz K, Kakularam KR, Adel S, et al. Conversion of pro-inflammatory murine Alox5 into an anti-inflammatory 15S-lipoxygenating enzyme by multiple mutations of sequence determinants. Arch Biochem Biophys 2012;530(1):40-7
   Google Scholar
• Johansson AS, Haeggström JZ, Hultenby K, Palmblad J. Subcellular localization of leukotriene receptors in human endothelial cells. Exp Cell Res 2010;316(17):2790-6
   Google Scholar
• Johansson AS, Haeggström JZ, Palmblad J. Commonly used leukotriene B4 receptor antagonists possess intrinsic activity as agonists in human endothelial cells. Effects on calcium transients, adhesive events and mediator release. Prostaglandins Leukot Essent Fatty Acids 2011;84(3-4):109-12
   Google Scholar
• Rasmussen SG, DeVree BT, Zou Y, et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011;477(7366):549-55
   PubMed Web of Science ®Google Scholar